Loading
Anatomic Stage III Breast Cancer AJCC V8 / Anatomic Stage Ii Breast Cancer AJCC V8 / Anatomic Stage I Breast Cancer AJCC V8 · Phase 2 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 2 trial—currently recruiting—designed to evaluate imlunestrant and abemaciclib in ER+ HER2− breast cancer patients with detectable circulating tumor DNA after initial treatment. No outcome data are available in this registry record; the study is in active enrollment and results have not yet been posted.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized…; age from 18 Years. Intervention: Treatment (abemaciclib, imlunestrant). n = 42. 1 site: United States.
This is a registered Phase 2 trial—currently recruiting—designed to evaluate imlunestrant and abemaciclib in ER+ HER2− breast cancer patients with detectable circulating tumor DNA after initial treatment. No outcome data are available in this registry record; the study is in active enrollment and results have not yet been posted.
Recruitment is ongoing; interim and final efficacy and safety data are not yet available.
Once results are reported, this trial may inform whether adding an estrogen receptor antagonist (imlunestrant) to CDK4/6 inhibition (abemaciclib) clears circulating tumor DNA in the MRD setting, a finding that could support adjuvant or maintenance strategies. Clinicians should await published efficacy and safety outcomes before considering clinical adoption.
Phase 2 trial in a recruiting stage with no results reported; measures a surrogate endpoint (ctDNA clearance) in an adjuvant minimal residual disease setting.
As stated by the source record.
Quoted from the source exactly as published.
Once results are reported, this trial may inform whether adding an estrogen receptor antagonist (imlunestrant) to CDK4/6 inhibition (abemaciclib) clears circulating tumor DNA in the MRD setting, a finding that could support adjuvant or maintenance strategies. Clinicians should await published efficacy and safety outcomes before considering clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07191717). This is a study registration, not published results. Lead sponsor: Jonsson Comprehensive Cancer Center. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 42 participants (ESTIMATED). Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma. Interventions: DRUG: Abemaciclib; PROCEDURE: Biospecimen Collection; DRUG: Imlunestrant; OTHER: Questionnaire Administration; PROCEDURE: Radiologic Imaging Procedure. Primary outcome measures: Rate of circulating tumor deoxyribonucleic acid (ctDNA) clearance , After 12 cycles (Cycle length = 28 days). Brief summary: This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease). Estrogen can cause the growth of breast cancer cells. Imlunestrant lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Imlunestrant and abemaciclib may be effective in treating patients with ER+ breast cancer who have minimal residual disease.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.